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Sialophorin, or CD43 (1), also known as leukosialin (2, 3) and large sialoglycoprotein
(4), is an abundant, heavily glycosylated, sialic acid-bearing surface protein on human
lymphocytes (5). The molecule is defective on lymphocytes of patients with the in-
herited immune deficiency Wiskott-Áldrich syndrome (5). Anti-CD43 mAb was shown
to be a potent inducer oflymphocyte proliferation (6), suggesting that CD43 is the
surface receptor of a lymphocyte stimulation pathway.
Sialophorin (CD43) is also an abundant surface molecule on blood monocytes
(7), cells that play critical roles in immune defense mechanisms. Monocytes can be
activated to enhanced defense functions by a number of agents, including cytokines
such as IFN-y(8) and bacterial cell wall products (9). Activated monocytes are charac-
terized by the ability to kill certain microorganisms and tumorcells (10) and to pro-
duce reactive oxygen intermediates, including hydrogen peroxide (11).
In this study we tested the antisialophorin mAb L10 (5) for its ability to trigger
activation of human monocytes. We show that the anti-CD43 mAb induces activa-
tion of monocytes as judged by increased hydrogen peroxide-producing capacity.
Activation of monocytes by anti-CD43 mAb is compared with activation of mono-
cytes by rIFN-y. The involvement ofhomotypic adhesion in the pathway of mono-
cyte activation by anti-CD43 mAb is demonstrated.
Materials and Methods
Antibodies.
￿
Mouse mAbs were used as follows: 1,10, an IgGl, against human sialophorin
(CD43) (5); TA-1, an IgG2a, against human LFA-1 (CDlWCD18) (12); mAb 44 (a gift of
Dr. Robert Todd III, University of Michigan Medical School, Ann Arbor, MI), an IgG2a
against human Mol a subunit (CD11b) (13, 14); mAb 60.3 (a gift ofDr. Patrick Beatty, Fred
Hutchinson Cancer Research Center, Seattle, WA), an IgGl against CD18, the common 0
subunit of human LEA-1, Mol, and p150,95 (15); and the irrelevant control mAb M12, an
IgGl against guinea pig CDllb (16). TA-1 precipitated Mr 170,000 and 95,000 polypeptides
from lysates of '25I-labeled monocytes, and the anti-CD11b mAb OKM1 (17) (Ortho Diag-
nostic Systems, Inc., Westwood, MA), tested in parallel, precipitated M, 155,000 and 95,000
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polypeptides (T. W. LeBien, unpublished findings). The failure of TA-1 to precipitate CDllb
indicates that TA-1 recognizes the ot, rather than the /3, subunit of LFA-1. The IgG content
of ascites was quantified by radial immunodiffusion (18) in agar gels containing 0.01 vol of
rabbit anti-mouse IgG antiserum (Miles Laboratories, Inc., Naperville, IL). Homogeneous
antibodies were prepared from ascites by adherence to protein A-agarose at pH 8.0 and elu-
tion at low pH (19).
Reagents.
￿
rIFN-,y (106 U/ml) was from Amgen Biologicals, Thousand Oaks, CA. Medium
199, RPMI 1640, and HBSS were from Gibco Laboratories, Grand Island, NY; gentamycin
was from M. A. Bioproducts, Walkerville, MD; and FCS was from HyClone Laboratories,
Logan, UT. Culture solutions and supernatants were assayed with a chromogenic Limulus
amoebocyte lysate assay (M. A. Bioproducts) to insure that LPS content was 50.01 ng/ml.
Cells.
￿
Human peripheral bloodfrom healthy volunteers was drawn into plastic vials con-
taining acid-citrate-dextrose (NIH formula A; Fenwal Laboratories, Deerfield, IL), and
mononuclear cells were purified by Ficoll-Hypaque centrifugation. The mononuclear cells
(2 x 105 in 200 lil RPMI 1640 medium with 10% FCS) were incubated in 96-well tissue
culture plates (Becton Dickinson & Co., Oxnard, CA) for 1 h at 37°C. Nonadherent material
was decanted and the wells were washed with RPMI 1640 at 37°C . The adherent cells (N0.5 x
105/well), -96% monocytes as judged by esterase staining (20), were cultured in RPMI 1640
with 10% FCS and 50,ug/ml gentamycin for 24 h and were washed with RPMI 1640. Platelet
contamination, quantified at this point by microscopic examination, was 58 platelets/100
monocytes.
Monocyte Activation.
￿
mAb (ascites or purified IgG) or IFN-'Y in RPMI 1640 containing
10% FCS were added to washed 1-d-old adherent monocytes, which were then cultured for
0.5-48 h.
Hydrogen Peroxide Assay.
￿
Secretion of H202 in response to PMA was measured by the
modified scopoletin fluorescent assay (21). The monolayers were incubated with 7 'UM
scopoletin, 20 Etg/ml horseradish peroxidase, 65 ng/ml PMA, and 1 mM NaN3 in a volume
of 200 p.l. DNA content, determined in parallel wells, as described (22), indicated that none
ofthe experimental treatments altered the number ofcells per well. Hydrogen peroxide produc-
tion was expressed as ng H202/Fig DNA/h.
AssayforMonocyteAggregation.
￿
All plates were assigned codedidentification by an individual
not otherwise involved in the study. Wells were scored for aggregates, defined as the associa-
tion of 310 cells, using a Nikon phase contrast microscope.
Results
Anti-CD43 mAb LIO Induces Hydrogen Peroxide Production in HumanMonocytes.
￿
Iso-
lated human blood monocytes were allowed to mature in culture for 1 d, then treated
with the anti-CD43 mAb L10 for 48 h . Hydrogen peroxide release measured in the
presence ofthe triggeringagent PMA was increased five- to sevenfold in L10-treated
monocytes in comparison with monocytes treated without antibody or with subclass-
matched irrelevant antibody (M12 mAb) (Fig. 1). Optimal hydrogen peroxide-pro-
ducing capacity was induced by 15 ttg/ml L10, and higher levels had no additional
effect . L10 used in these experiments was pure IgG, indicating that its action is not
attributable to other components. The level of peroxide-producing capacity induced
by optimal L10 mAb concentrations (1.6 ± 0.3 nmol H202/tig DNA/h) was com-
parable with that induced by optimal levels of rIFN-y (1.3 ± 0.4 nmol H202/p,g
DNA/h) (mean ± SE ofsix experiments; e.g., Fig. 1). As previously shown for IFN-
T-activated monocytes, L10-treated monocytes require the triggering agent PMA
to be present in the hydrogen peroxide assay (not shown).
Time Course of Enhancement ofHydrogen Peroxide Capacity Induced by L10 mAb.
￿
L10
induction of increased hydrogen peroxide-producing capacity of monocytes is a time-
dependent reaction with maximum capacity reached after 24 h with 15 hg/ml L10L
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(Fig. 2). In contrast, in IFN-y-treated monocytes, maximum peroxide production
was reached after 48 h with 200 U/ml (Fig. 2). Further increase of the IFN-y con-
centration did not shorten the time (not shown). Thus, maximum hydrogen
peroxide-producing capacity is reached after 24 h of treatment of monocytes with
optimal L10 concentration or 48 h with optimal IFN-y.
Anti-CD43 mAb Induces Homotyßic Adhesion ofMonocytes.
￿
The adherence proper-
ties of 1,10-treated monocytes were also examined, since IFN-y-induced monocyte
activation is known to proceed via a stage involving homotypic cell adhesion (23).
When 1-d-old adherent monocytes were treated with L10 for 24 h, increased numbers
of aggregates were found relative to monocytes treated with subclass-matched ir-
relevant antibody (Fig. 3) or monocytes incubated without antibody (not shown).
The increase of monocyte aggregation was dependent on L10 concentration with
maximal aggregation at 5-10 hg/ml; 20 and 40 /Ag/ml L10 were partially inhibitory
(Fig. 3). The level of monocyte aggregation induced by L10 mAb was comparable
with that induced by IFN-y (shown below).
Time Course ofMonocyte Aggregation Induced by theAnti-CD43Antibody L10.
￿
Mono-
cyte aggregation induced by L10 is a time-dependent process, with significant aggre-
gation detected after 1 and 4 h, and maximal aggregation reached at 8 h of L10
treatment (Fig. 4). The requirement for 1-8-h incubation strongly suggests that L10
does not function solely as a crosslinking agent. L10-induced monocyte aggregation
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FIGURE 1. Hydrogen peroxide-producing
capacity induced in monocytes byvarying con-
centrations of L10 mAb. Isolated adherent
monocytes, which hadmatured in culture for
1 d, were treated with the indicated concen-
tration ofpurified L10IgG("), the IgGfrac-
tion ofthe irrelevant mAbM12(O), or rIFN-y
(A). The hydrogen peroxide-producing ca-
pacities measured after 48 h of treatment are
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FIGURE 2.
￿
Time course of enhancement of
hydrogen peroxide-producing capacity of
monocytes treated with L10 mAb or IFN-y.
1-d-old adherent monocytes were cultured for
the indicated time with L10 ascites at 15 wg
IgG/ml ("), 15 Wg IgG/ml of the irrelevant
M12 ascites (O), or rIFN-y at 200 U/ml (A).
Thehydrogen peroxide production values are
means t SE of triplicate determinations.262
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FIGURE 3 .
￿
Homotypic adhesion of monocytes
-I
￿
induced by varying concentrations of L10 mAb .
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FIGURE 4 .
￿
Time course ofhomotypic adhesion
ofmonocytes induced by L10 mAb or IFN-y . Be-
ginning 1 d after isolation, adherent monocytes
were treatedwith 10 fig/ml purified L10 IgG (" ),
b
￿
200 U/ml ofrIFN-y (A), or medium alone (O) .
The number ofaggregates/well are means f SE
no additive
￿
of quintuplicate determinations .
remained maximal at 12, 24, and 48 h (Fig . 4) . In contrast, monocyte aggregation
induced by IFN-1' is nondetectable at 12 h and maximal at 24 h (Fig . 4) .
Role ofCations in Monocyte Aggregation Induced by Anti-CD43 .
￿
When monocytes were
depleted of Mg
2+ and Ca
2+' induction of aggregation by L10 was almost completely
abrogated (Table I) . The capacity of the cells to undergo L10-induced homotypic
adhesion was restored by addition of 1 mM Mg2+ ; addition of Cat+ had no effect .
Thus, Mg2+ is required to support L10-induced monocyte aggregation, a finding
inconsistent with mechanisms in which L10 acts solely as a crosslinking agent.
The Anti-LFA-1 Antibody TA-1 Inhibits Monocyte Aggregation Induced by theAnti-CD43
Antibody L10.
￿
IFN-,y-induced homotypic adhesion of monocytes was shown to in-
TABLE I
Aggregation ofMonocytes Induced by LIO rnAb is Mg" Dependent
Adherent monocytes that had been cultured for 1 d in complete medium, were
incubated for 2 h in HBSS + FCS (complete medium) or Mg 2+/Ca 2+-free
HBSS + dialyzed FCS (depleted medium) . L10 ascites diluted 1:100 in com-
plete or depleted medium were added, and cell aggregation was evaluated after
a further 4-h incubation . Where indicated, 1 mM Mg2+ and/or Ca t+ was added
to depleted cell cultures simultaneously with L10 addition . The data are the means
± SE of quadruplicate determinations .
Medium Without
Aggregates
mAb
per well
With L10 mAb
Complete 99 ± 24 354 ± 42
Depleted 45 ± 11 107 ± 17
Depleted, + Mg2+ 174 ± 33 469 ± 54
Depleted, + Cat+ 15 ± 5 148 ± 15
Depleted, + Mg 2+ and Ca t+ 147 t 30 408 ± 19m
w
u
rn
0
time of culture (h)
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FIGURE 5.
￿
Homotypic adhesion of monocytes
induced by L10 rnAb is inhibited by TA-1 mAb.
1-d-old adherent monocytes were cultured for the
indicated time with medium alone (O), TA-1 mAb
ascites at 1:10 dilution (A), 10 hg/ml ofL10 IgG
("), and L10 + TA-1 (A). The number of ag-
gregates/well are means ± SE of triplicate de-
terminations. Similarresults were obtained with
L10 mAb at 20 ttg/ml (not shown).
volve the heterodimeric surface molecule LFA-1 (CDlla/CD18) (23). To determine
whether LFA-1 is involved in LIO-induced homotypic adhesion, the monocytes were
treated with L10 mAb in the presence of the anti-LFA-la (anti-CDlla) mAb TA-1 .
TA-1 mAb completely abrogated the induction of monocyte aggregation by 10 or
20 ug/ml L10 mAb (Fig. 5). The mAb 44, an anti-Mol-a (anti-CD11b) antibody,
at the same concentration, had no effect on 1,10-induced monocyte aggregation(not
shown). The mAb 60.3 (anti-CD18) directed against the common (3 subunit of Mol
and LFA-1 caused slight inhibition of1,10-induced monocyte aggregation (not shown).
These findings indicate that L10-induced monocyte aggregation is a Mgt+ -requiring
process, that like IFN-y-induced monocyte aggregation, involves LFA-1 surfacemol-
ecules .
Discussion
The present study demonstrates that L10, an mAb that binds to sialophorin (CD43),
induces increased hydrogen peroxide-producing capacity and homotypic adhesion
of human monocytes, two characteristics associated with the activated state of these
cells. The requirement for Mgt+ and 1-8-h incubation strongly indicates that L10-
induced monocyte aggregation is not a simple case of antibody crosslinking of cells.
In direct comparisons, the extent of L10-induced enhancement of hydrogen
peroxide-producing capacity and homotypicadhesion were found to be comparable
with the effects induced by the prototypic monocyte-activating agent IFN-y.
The finding that Mgt' depletion abrogates, and Mgt' reconstitution restores,
1,10-induced monocyte aggregation suggested the involvement ofadhesion molecules
of the Leu-CAM family. These are heterodimer surface glycoproteins consisting of
CD18 and either CD11a (LFA-1), CD11b (Mol, Mac-1), or CD11c (p150,95) (reviewed
in reference 24). LFA-1 has been shown to mediate heterotypic and homotypic in-
teractions of leukocytes, including IFN-y-induced aggregation of monocytes (23).
TA-1, a LFA-la mAb, reduced L10-induced aggregation to baseline levels, indi-
cating that LFA-1 is instrumental in L10-induced monocyte aggregation. An anti-
CD18 mAb, 60.3 (anti-a chain), had a slight inhibitory effect on L10-inducedmonocyte
aggregation. A previous study showed that IFN-y-induced monocyte aggregation,
like L10-induced monocyte aggregation, was inhibited completely by anti-LFA-Ici
mAb, but only partially by an anti-CD18 mAb that was completely inhibitory in
a lymphocyte system (23). The lesser sensitivity of IFN-y-induced monocyte aggre-
gation to inhibition by anti-CD18 mAb was attributed to the presence on monocytes
of multiple CD18 heterodimers (23).264
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We do not know whether there is any relatedness ofthe findings reported here,
i.e., activation ofmonocytes by anti-CD43 mAb, and an earlier study in the mouse
system demonstrating activation ofmacrophages by mAb against both subunits of
CD11b/CD18 (25). Treatment ofhuman monocytes with the anti-CDllb mAb 44
failed to stimulate hydrogen peroxide-generating capacity (H. G. Remold, unpub-
lished results) or homotypic adhesion; additional anti-CDllb/CD18 mAbs were not
examined.
Human sialophorin (CD43), the surfacemolecule recognized by L10 mAb, is found
on thymocytes, T lymphocytes, some B lymphocytes, neutrophils, monocytes, and
platelets (6, 7). It is a highly glycosylated acidic molecule (-60% carbohydrate),
consisting ofa COOH-terminal intracellular region subject to phosphorylation by
protein kinase C (26), a single transmembrane region, and an extracellular region
(27). Sialophorin has one N-linkedcarbohydrate unit and 80-90 sialic acid-bearing
0-linked units, distributed, more or less uniformly, throughout the -235-amino acid
extracellular region (27, 28).
The present study is the first examination of sialophorin function in monocytes,
but the role ofsialophorin inlymphocyte function has received some attention. Sur-
face CD43 is deficientand/or defective inlymphocytes ofpatients with the inherited
immune deficiency Wiskott-Aldrich syndrome (5). Sialophorin is thought to be a
component of a pathway ofT cell activation, since L10 mAb triggers proliferation
ofhumanT lymphocytes (6). L10-inducedlymphocyte proliferationis quantitatively
comparable with lymphocyte proliferation induced by mAbs directed against
CD3/TCR, and both processes are monocyte dependent and lead to increased sur-
face expression ofHLA-DR and IL-2-R (6). The putative natural ligand for CD43
is unknown. Two other anti-CD43 mAbs, BIB6 and E11B, induce IL-2 secretion
by lymphocytes, synergize with PMA in inducing lymphocyte proliferation, and
induce lymphocyte aggregation (4). Lymphocyte aggregation inducedby these anti-
CD43 mAbs, like the anti-CD43-induced monocyte aggregationdocumentedin this
study, requires the presence of Mg2+ and is abrogated by anti-LFA-1 mAb (4).
Brief incubation oflymphocytes with L10 mAb was shown to generate increased
levels ofdiacyl glycerol, inositol phosphates, and intracellular Ca2+, as well as con-
version ofprotein kinase C from a soluble to a membrane-associated form (29). All
ofthese L10-induced events areknownto be associatedwith proteinkinase C activa-
tion in other systems (30). Moreover, two of these early changes, increased levels
ofinositol phosphates and intracellular Cat+, were also demonstrated in monocytes
treated with L10 (29).
Since monocyte activation induced by L10 and IFN-y havemultiple common char-
acteristics, the possibility was considered that L10 acts via the IFN-y pathway. L10-
induced release of IFN-y from lymphocytes is a highly unlikely explanation, first
of all, because the cell populations were 395% monocytes. It is certain that IFN-y
and L10bind to different molecules, since thereceptors forbothhave been sequenced
(27, 31). Most importantly, themorerapid appearance ofactivation-associated changes
in L10-treated monocytes relative to IFN-y-treated monocytes provides strong evi-
dence that L10 action does not depend on the IFN-y-R pathway.
Indeed, the documentation ofparallel changes in anti-CD43-treated lymphocytes
and anti-CD43-treated monocytes, i.e., early signalinginvolvinginositol phosphates,
Ca2+, and protein kinase C, and the appearance at later times ofhomotypic adhe-NONG ET AL.
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sion, suggest that the pathway of CD43 activation is independent ofmolecules, like
the IFN-y-R and the TCR/CD3 complex, that are specific to only one of these cells.
Cumulatively, these findings indicate that CD43 is the surface receptor of an inde-
pendent pathway of activation of lymphocytes and macrophages; the pathway has
early events common to lymphocytes and monocytes and later events specific to each
cell.
Summary
Treatment ofhuman monocytes for 24-48 h with the anti-CD43 mAb L10 caused
five- to sevenfold stimulation of hydrogen peroxide-producing capacity, an estab-
lished characteristic of activated monocytes. Peroxide-producing capacity induced
by L10 antibody (1 .6 ± 0.3 nmol H202/wg DNA/h) was comparable with that in-
duced by IFN-y (1.3 ± 0.4 nmol H202/Ag DNA/h), but appeared more rapidly
(maximal at 24 h) than in the ON-y-treated monocytes (maximal at 48 h) .
Treatment of monocytes with L10 mAb also caused dramatic increase in aggrega-
tion (homotypic adhesion). Induction of monocyte aggregation by L10 mAb required
incubation for 1-8 h in the presence of Mgt+ and was abrogated by TA-1, an anti-
LFA-1-a mAb. Thus, L10-induced monocyte activation proceeds via a Mgt+-requir-
ing aggregation stage involving LFA-1. Whereas the extent of monocyte aggregation
induced by L10 mAb and by IFN-y were comparable, the L10-induced aggregation
occurred more rapidly (maximal at 8 h) than the IFN-y-induced aggregation (max-
imal at 24 h) . The more rapid appearance of aggregation and increased hydrogen
peroxide capacity in L10-treated monocytes suggests that the 1,10-induced activa-
tion pathway is independent of IFN-y- and IFN-y-R dependent events. These findings
suggest that the surface molecule CD43 is the receptor of an independent activation
pathway that leads in lymphocytes to proliferation and in monocytes to activation.
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